An Approach to Reducing Annotation Costs for BioNLP
Michael Bloodgood and K. Vijay-Shanker. 2008. An approach to reducing annotation costs for BioNLP. In Proceedings of the Workshop on Current Trends in Biomedical Natural Language Processing, pages 104-105, Columbus, Ohio, June. Association for Computational Linguistics.
MetadataShow full item record
There is a broad range of BioNLP tasks for which active learning (AL) can significantly reduce annotation costs and a specific AL algorithm we have developed is particularly effective in reducing annotation costs for these tasks. We have previously developed an AL algorithm called ClosestInitPA that works best with tasks that have the following characteristics: redundancy in training material, burdensome annotation costs, Support Vector Machines (SVMs) work well for the task, and imbalanced datasets (i.e. when set up as a binary classification problem, one class is substantially rarer than the other). Many BioNLP tasks have these characteristics and thus our AL algorithm is a natural approach to apply to BioNLP tasks.
Showing items related by title, author, creator and subject.
Evaluation of national output and scientific productivity in the biomedical field of several East European countries in the 1989-1995 time period using MEDLINE Baykoucheva, S (Kent State University School of Library and Information Science, 1997)
Finite Element Modeling and Cellular Studies on Controlled Pores with Sub-Surface Continuity for Biomedical Applications Lambert, Paul Keslar (2012)This work investigated a novel process for improving the reliability of load-bearing joint prosthetics, in which electrical discharge machining (EDM) is used to create pores with sub-surface continuity on a conventionall ...
Biomedical Innovation and the Politics of Scientific Knowledge: A case study of Gardasil Clark, Aleia Yvonne (2008)Vaccine development represents a special case where historically, public health priorities are central. Trends of privatization have increased the role played by pharmaceutical and biotech companies in developing new ...